MAPK3 and neoplasm: ASN007 [113], LY3214996 [114], GDC-0994 [115], and MK-8353 [116] are a few ATP-competitive Erk1/2 inhibitors that have been found, and several of them have shown considerable anti-tumor effects in cancers carrying Ras mutations.